Type

medicine

Development of new stem cell type may lead to advances in regenerative medicine

IMAGE

IMAGE: Drs. Jun Wu, Leqian Yu, Yulei Wei and colleagues isolated a new type of pluripotent stem cell from mice, horses, and humans, named XPSCs, which are capable of generating chimeras…
view more 

Credit: Photo illustration by Leqian Yu

DALLAS – Dec. 3, 2020 – A team led by UT Southwestern has derived a new “intermediate” embryonic stem cell type from multiple species that can contribute to chimeras and create precursors to sperm and eggs in a culture dish.

The findings, published online this week in Cell Stem Cell, could lead to a host of advances in basic biology, regenerative medicine, and reproductive technology.

Cells in early embryos have a range of distinct pluripotency programs, all of which endow the cells to create various tissue types in the body, explains study leader Jun Wu, Ph.D., assistant professor of molecular biology. A wealth of previous research has focused on developing and characterizing “naïve” embryonic stem cells (those about four days post-fertilization in mice) and “primed” epiblast stem cells (about seven days post-fertilization in mice, shortly after the embryo implants into the uterus).

However, says Wu, there’s been little progress in deriving and characterizing pluripotent stem cells (PSCs) that exist between these two stages – largely because researchers have not been able to develop a paradigm for maintaining cells in this intermediate state. Cells in this state have been thought to possess unique properties: the ability to contribute to intraspecies chimeras (organisms that contain a mix of cells from different individuals of the same species) or interspecies chimeras (organisms that contain a mix of cells from different species) and the ability to differentiate into primordial germ cells in culture, the precursors to sperm and eggs.

For this study, the researchers successfully created intermediate PSCs, which they named “XPSCs” from mice, horses, and humans.

Wu says that these results could eventually lead to an array of advances in both basic and applied research. For example, looking at gene activity in XPSCs from different species and interspecies chimeras could help researchers understand which signatures have been conserved through evolution. Examining the communication between cells in chimeras may help scientists identify strategies that could be used to accelerate the development of tissues and organs from stem cells used for transplantation. And using chimera-derived primordial germ cells to create sperm and eggs could aid in preserving endangered animal species and advancing infertility treatments.

“These XPSCs have enormous potential. Our study helps open the door to each of these possibilities,” says Wu, who is a Virginia Murchison Linthicum Scholar in Medical Research.

Wu notes that developing XPSCs presented a special challenge because the conditions that keep naïve PSCs in a stable state are exactly the opposite from those that stabilize primed PSCs. While culture conditions for naïve PSCs must activate a WNT cell-signaling pathway and suppress the FGF and TGF-ß pathways, the conditions to maintain primed PSCs must suppress WNT and activate FGF and TGF-ß.

Aiming for the preferred environment for XPSC derivation, Wu and his

Read More
medicine

Sports Medicine Market Analysis by Applications, End-Users, Top Companies, Future Growth Opportunities, Product Type, Global Forecast To 2020

The MarketWatch News Department was not involved in the creation of this content.

Japan, Japan, Wed, 02 Dec 2020 14:20:31 / Comserve Inc. / — Over the years, the sports medicine market has witnessed various technological advancements made to ensure and provide better recovery and rehabilitative measures for injuries caused during sports or physical activities.

The sports medicine market comprises products and devices used by professional or non-professional athletes or sportspersons to prevent and protect themselves from injuries as well as devices that enhance performance. The sports medicine products play an important role in the rehabilitation, recovery, protection, endurance, and monitoring of athletes while playing sports. Over the years, the sports medicine market has witnessed various technological advancements made to ensure and provide better recovery and rehabilitative measures for injuries caused during sports or physical activities.

These advancements have led to the development of new products and therapies to treat sports injuries. Various market players are focusing on the introduction of newer products and treatment options for sports injuries. A number of key players are competing to secure larger shares of the market by launching new products. Arthrex, Inc. (U.S.), Smith & Nephew PLC (U.K.), DePuy Synthes Companies (U.S.), Stryker Corporation (U.S.), and CONMED Corporation (U.S.) are the top five players of this market

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-61031

“The Final Report will cover the impact analysis of COVID-19 on this industry (Global And Regional Market).”

In 2015, the body reconstruction & repair products segment is expected to account for the largest share of the global sports medicine market, by product, while the knee injuries segment is expected to account for the largest share of the sports medicine market, by application.

In 2015, North America is expected to account for the largest share of the global sports medicine market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). In the coming years, the sports medicine market is expected to witness the highest growth rate in the Asia-Pacific region, with emphasis on India, China, and Japan. The entry of international players, increasing government initiatives, and rising awareness regarding sports medicine in emerging nations like India and China are expected to drive the market in these regions.

The sports medicine market witnesses high competitive intensity as there are several big and many small firms with similar product offerings. These companies adopt various growth strategies (agreements, partnerships, joint ventures, geographic expansions, new product launches, and acquisitions) to increase their market shares and establish a strong foothold in the global market.

“The Final Report will cover the impact analysis of COVID-19 on this industry (Global And Regional Market).”

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market

Read More
medicine

American College of Lifestyle Medicine Launches Bill of Rights to Raise Awareness of Lifestyle Medicine’s Role in Type 2 Diabetes Informed Consent and Treatment

The Bill of Rights is a companion to ACLM’s recently launched “Reversing Type 2 Diabetes and Insulin Resistance with Lifestyle Medicine” 18-hour, 20-module, evidence-based CME/CE accredited online course for physicians and health professionals. This is the first comprehensive educational curriculum offered to equip physicians and other health professionals to treat and reverse type 2 diabetes and insulin resistance.  In addition, ACLM recently published a position paper, “Type 2 Diabetes Remission and Lifestyle Medicine: A Position Statement from the American College of Lifestyle Medicine.” ACLM will also present a free webinar, “The Reversibility of Type 2 Diabetes with Lifestyle Medicine—Q & A” on Thursday, Nov. 12 at 12 p.m. CST.

ACLM defines Lifestyle Medicine as the use of an evidence-based, whole food, plant-predominant dietary lifestyle, regular physical activity, restorative sleep, stress management, avoidance of risky substances and positive social connection as a primary therapeutic modality for treatment, reversal and prevention of chronic disease. Addressing lifestyle is the first step in type 2 diabetes and other chronic disease treatment and management guidelines, but it has been overlooked due to a lack of physician training in lifestyle, barriers to practice and a lack of consumer understanding. 

“We believe that a patient does not give fully informed consent if this option is not presented to them at the time of diagnosis,” said ACLM Founding President John Kelly, MD, DipABLM, lead faculty for the new course. “COVID-19 has highlighted the vulnerabilities created by type 2 diabetes, amplifying the urgent need to restore health to those impacted by this lifestyle-related chronic disease, as opposed to simply managing it.”

“COVID-19 has exposed the long-standing issue of racial health disparities in America, as people of color have been disproportionally affected by the pandemic,” said ACLM President Cate Collings, MD, DipABLM.  “While the causes of racial health disparities are many, and include the range of social determinants of health, the most devastating impact is from the significantly higher incidence of chronic disease, most notably type 2 diabetes.

“If you are talking about racial health disparities and are not focused on the disparate impact of type 2 diabetes, you are missing the heart of the matter.”

“Truly addressing racial health disparities will only happen when our nation recognizes the role of lifestyle and trains its clinicians accordingly, fully informs patients, removes the barriers to practicing Lifestyle Medicine and rewards physicians and health professionals for restoring health rather than merely managing disease,” said Kelly. “ACLM is actively addressing each of these areas.”

Diabetes has a devastating impact on the quality of life of millions of Americans.  Treatment for diabetes is also a major contributor to the country’s health care spending. According to the Centers for Disease Control and Prevention, 90 percent of the nation’s $3.3 trillion in annual health care expenditure pays for the treatment of chronic health conditions, including type 2 diabetes. In the United States

Read More
medicine

Global Sports Medicine Device Market to 2025 – by Manufacturers, Regions, Technology, and Product Type

DUBLIN, Nov. 10, 2020 /PRNewswire/ — The “Sports Medicine Device Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Product Type” report has been added to ResearchAndMarkets.com’s offering.

This report is a professional and in-depth study on the current state of the global Sports Medicine Device market with a focus on the Chinese market. The report provides key statistics on market of Sports Medicine Device. It is a valuable source of guidance and direction for companies and individuals interested in Sports Medicine Device industry.

Key points of Sports Medicine Device Market Report:
1. The report provides a basic overview of Sports Medicine Device industry including: definition, applications and manufacturing technology.
2. The report explores Global and Chinese major players in Sports Medicine Device market. In this part, the report presents the company profile, product specifications, capacity, production value, and 2015-2020 market shares for each company.
3. The report depicts the global and Chinese total Sports Medicine Device market including: capacity, production, production value, cost/profit, supply/demand and Chinese import/export, by statistical analysis.
4. The global Sports Medicine Device market is further divided by company, by country, and by application/type for the competitive landscape analysis.
5. The report then estimates 2020-2025 development trends, analyse upstream raw materials, downstream demand, and current market dynamics of Sports Medicine Device market.
6. The report makes some important proposals for a new project of Sports Medicine Device Industry before evaluating its feasibility.
7. Overall, the report provides an in-depth insight of 2015-2025 global and Chinese Sports Medicine Device market covering all important parameters.

Key Topics Covered:

1.: Introduction of Sports Medicine Device Industry
1.1 Brief Introduction of Sports Medicine Device
1.2 Development of Sports Medicine Device Industry
1.3 Status of Sports Medicine Device Industry

2.: Manufacturing Technology of Sports Medicine Device
2.1 Development of Sports Medicine Device Manufacturing Technology
2.2 Analysis of Sports Medicine Device Manufacturing Technology
2.3 Trends of Sports Medicine Device Manufacturing Technology

3.: Analysis of Global Key Manufacturers
3.1 Arthrex
3.1.1 Company Profile
3.1.2 Product Information
3.1.3 Capacity Production Price Cost Production Value
3.1.4 Contact Information
3.2 Smith & Nephew
3.2.1 Company Profile
3.2.2 Product Information
3.2.3 Capacity Production Price Cost Production Value
3.2.4 Contact Information
3.3 Stryker
3.3.1 Company Profile
3.3.2 Product Information
3.3.3 Capacity Production Price Cost Production Value
3.3.4 Contact Information
3.4 Depuy Synthes/Johnson & Johnson
3.4.1 Company Profile
3.4.2 Product Information
3.4.3 Capacity Production Price Cost Production Value
3.4.4 Contact Information
3.5 Zimmer Biomet
3.5.1 Company Profile
3.5.2 Product Information
3.5.3 Capacity Production Price Cost Production Value
3.5.4 Contact Information
3.6 Karl Storz
3.6.1 Company Profile
3.6.2 Product Information
3.6.3 Capacity Production Price Cost Production Value
3.6.4 Contact Information
3.7 Conmed
3.7.1 Company Profile
3.7.2 Product Information
3.7.3 Capacity Production Price Cost Production Value
3.7.4 Contact Information
3.8 Wright
3.8.1 Company Profile
3.8.2 Product Information
3.8.3 Capacity Production Price Cost Production Value
3.8.4 Contact Information
3.9 Medshape
3.9.1 Company Profile
3.9.2 Product Information
3.9.3 Capacity Production Price Cost Production Value
3.9.4

Read More
health

Type 2 diabetes drug recalled over concerns medication contaminated with possible carcinogen

Metformin, a medication to treat type 2 diabetes, is facing a recall over concerns it has been contaminated with a possible cancer-causing substance. 

Nostrum Laboratories Inc., the maker of Metformin, announced it is voluntarily recalling two lots of the medication – Metformin HCl Extended-Release Tablets, USP 750 mg – because the lots have been found to contain above-acceptable limits of nitrosamine, also known as NDMA, a “probable human carcinogen,” per the recall announcement posted to the U.S. Food and Drug Administration’s (FDA) website on Monday. 

This isn’t the first time excess levels of NDMA in medications have prompted recalls. In the past, certain blood pressure and heartburn medications have been affected.

This isn’t the first time excess levels of NDMA in medications have prompted recalls. In the past, certain blood pressure and heartburn medications have been affected.
(iStock)

“NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products and vegetables,” per the announcement. 

No adverse events related to the recalled medications have been reported to date, the company said. 

METHOD HAND SOAP RECALLED OVER BACTERIA CONTAMINATION CONCERNS 

The affected medications are packaged in HDPE bottles of 100 tablets, under NDC 29033-056-01, per the announcement on the FDA’s website. Lot numbers are MET200101 and MET200301. Both lots have an expiration date of May 2022. 

“The product can be identified as an off-white oblong tablet debossed with ‘NM7.’ Metformin HCl Extended-Release Tablets, USP 750 mg was distributed nationwide to wholesalers,” per the announcement. 

COLORADO HIKER WITH CORONAVIRUS-LIKE SYMPTOMS FOUND TO HAVE RARE, POSSIBLY LIFE-THREATENING DISEASE

“Nostrum Laboratories Inc. is notifying its distributors by letter and is arranging for return of all recalled products. Pharmacies that have Metformin HCl Extended-Release Tablets, USP 750 mg, which is being recalled, should return to place of purchase. Consumers should consult a health care professional to obtain a replacement or a different treatment option,” the announcement reads. “It could be dangerous for patients with type 2 diabetes to stop taking their Metformin without first talking to their health care professional. Consumers should contact their physician or health care provider if they have experienced any problems that may be related to taking this drug product.”

COTTONELLE FLUSHABLE WIPES RECALLED OVER BACTERIA CONCERNS

Consumers with additional questions can contact Nostrum Laboratories Inc. Medical Affairs at 816-308-4941 or email [email protected] 

This isn’t the first time excess levels of NDMA in medications have prompted recalls. In the past, certain blood pressure and heartburn medications have been affected.

Source Article

Read More
health

Catheter Market Research Report: By Type, Shape, End User

Catheter Market Research Report: By Type (Cardiovascular, Urological, Gastrointestinal, Neurovascular, Ophthalmic), Shape (Pigtail, Judkins Left, Judkins Right, Bypass, Amplatz), End User (Hospitals and Ambulatory Surgical Centers, Homecare Settings, Diagnostic Centers) – Global Industry Analysis and Growth Forecast to 2030

New York, Nov. 03, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Catheter Market Research Report: By Type, Shape, End User – Global Industry Analysis and Growth Forecast to 2030” – https://www.reportlinker.com/p05982489/?utm_source=GNW

The prevalence of chronic diseases, such as cancer, cardiovascular diseases, urinary tract infections, and neurological diseases, is increasing rapidly across the globe, which is leading to the rising demand for medical devices, such as catheters. For example, as per the Global Cancer Observatory 2018, the third leading cause of cancers globally was gastric cancer, which accounted for 783,000 deaths in 2018, rising from 723,000 deaths in 2012. In addition to this, more than one million cases of gastric cancers are diagnosed every year across the world. Similarly, the increasing cases of cardiovascular diseases are also projected to drive the demand for catheters in the years to come.

A catheter is a medical device that is passed into the bladder for draining urine. These devices are at time important for people who are not able to empty their bladders in the usual way, which can be due to different medical conditions. As per a P&S Intelligence report, the global catheter market is projected to attain a value of $36.0 billion by 2030, rising from $14.3 billion in 2019, advancing at an 8.8% CAGR during the forecast period (2020–2030). Different types of catheters are ophthalmic, urological, cardiovascular, neurovascular, and gastrointestinal.

In addition to this, these catheters also have the ability to remove toxic fluid from kidneys. Catheters have different shapes, namely amplatz, pigtail, bypass, judkins left, and judkins right, out of which, the demand for pigtail catheters was the highest in the past. The high adoption of these catheters can be ascribed to the fact that are flexible, smaller in size, ensure easy insertion for diagnosing or treating blockages in blood vessels, and less traumatic. The utilization of these catheters is further expected to be the highest in the near future due to their association with low rate of complications.

In conclusion, the demand for catheters is growing because of the surging prevalence of cardiovascular diseases around the world.
Read the full report: https://www.reportlinker.com/p05982489/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

Source Article

Read More
health

Type 2 diabetes drug metformin recalled over contamination with possible carcinogen

Nostrum Laboratories Inc., based in Kansas City, Missouri, announced Monday that it is voluntarily recalling its metformin HCl extended release tablets, USP 750 mg, according to a recall posted by the US Drug & Food Administration.
Testing revealed levels of nitrosamine, or NDMA, above acceptable limits in the recalled tablets.
The chemical NDMA is considered a possible carcinogen by the US Environmental Protection Agency. It’s an organic chemical used to make liquid rocket fuel and it can be a byproduct of manufacturing, including pharmaceutical manufacturing. It’s also found in water and foods, including meats, dairy and vegetables.

NDMA has also been found in certain blood pressure drugs and antacid.

This is the latest in a series of metformin recalls linked to potentially cancer-causing contaminants in the drugs.

Nostrum said it has not received any reports of adverse events related to the recall. The company also said it was notifying its distributors and arranging for the return of the recalled product.

The impacted product is packaged in HDPE bottles of 100 tablets, under NDC 29033-056-01. The affected Metformin HCl Extended Release Tablets, USP 750 mg lots are under NDC 29033-056-01, lot numbers MET200101 and MET200301 which expiration date 05/2022. It can be identified as an off-white oblong tablet debossed with “NM7.”

More than 34 million people in the US have diabetes — about 1 in 10 — with approximately 90 to 95% of them being diagnosed with type 2 diabetes, according to the US Centers for Disease Control and Prevention.

Source Article

Read More
health

Cancer Diagnostics Market Research Report by Diagnostic Type, by Indication – Global Forecast to 2025

Cancer Diagnostics Market Research Report by Diagnostic Type (Biopsy and Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers), by Indication (Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, and Kidney Cancer) – Global Forecast to 2025 – Cumulative Impact of COVID-19

New York, Oct. 26, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Cancer Diagnostics Market Research Report by Diagnostic Type, by Indication – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05913709/?utm_source=GNW

The Global Cancer Diagnostics Market is expected to grow from USD 140,325.96 Million in 2019 to USD 221,237.88 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.88%.

Market Segmentation & Coverage:
This research report categorizes the Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Diagnostic Type, the Cancer Diagnostics Market studied across Biopsy and Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers.

Based on Indication, the Cancer Diagnostics Market studied across Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer.

Based on Geography, the Cancer Diagnostics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Diagnostics Market including Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson & Company, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic Inc., Illumina Inc., Philips Healthcare, Qiagen NV, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc..

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Diagnostics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and

Read More
health

Cellular Health Screening Market Research Report by Test Type, by Sample Type – Global Forecast to 2025

Cellular Health Screening Market Research Report by Test Type (Heavy Metal Tests, Inflammation Tests, Multi-test Panels, Oxidative Stress Tests, and Telomere Tests), by Sample Type (Blood and Body Fluids) – Global Forecast to 2025 – Cumulative Impact of COVID-19

New York, Oct. 23, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Cellular Health Screening Market Research Report by Test Type, by Sample Type – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05913784/?utm_source=GNW

The Global Cellular Health Screening Market is expected to grow from USD 2,031.33 Million in 2019 to USD 3,740.69 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 10.71%.

Market Segmentation & Coverage:
This research report categorizes the Cellular Health Screening to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Test Type, the Cellular Health Screening Market studied across Heavy Metal Tests, Inflammation Tests, Multi-test Panels, Oxidative Stress Tests, and Telomere Tests.

Based on Sample Type, the Cellular Health Screening Market studied across Blood and Body Fluids.

Based on Geography, the Cellular Health Screening Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cellular Health Screening Market including Bio-Reference Laboratories Inc., Cell Science Systems Corporation, Cleveland HeartLab Inc., Genova Diagnostics Inc., Laboratory Corporation of America Holdings, Life Length S.L., Quest Diagnostics Incorporated, and SpectraCell Laboratories Inc.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cellular Health Screening Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering

Read More
health

Childhood Absence Epilepsy Treatment Market Research Report by Drug, by Disease Type – Global Forecast to 2025

Childhood Absence Epilepsy Treatment Market Research Report by Drug (Lamotrigine, Phase 2 Drugs, and Valproate), by Disease Type (Atypical Absence Seizures and Typical Absence Seizures) – Global Forecast to 2025 – Cumulative Impact of COVID-19

New York, Oct. 22, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Childhood Absence Epilepsy Treatment Market Research Report by Drug, by Disease Type – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05913817/?utm_source=GNW

The Global Childhood Absence Epilepsy Treatment Market is expected to grow from USD 181.92 Million in 2019 to USD 263.89 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.39%.

Market Segmentation & Coverage:
This research report categorizes the Childhood Absence Epilepsy Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug, the Childhood Absence Epilepsy Treatment Market studied across Lamotrigine, Phase 2 Drugs, and Valproate.

Based on Disease Type, the Childhood Absence Epilepsy Treatment Market studied across Atypical Absence Seizures and Typical Absence Seizures.

Based on Geography, the Childhood Absence Epilepsy Treatment Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Childhood Absence Epilepsy Treatment Market including AbbVie, Cavion, Inc., GlaxoSmithKline plc, Insys Therapeutics, Pfizer Inc., Pfizer Inc., and Teva Pharmaceutical Industries Ltd..

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Childhood Absence Epilepsy Treatment Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain,

Read More